Krystal Biotech, Inc. Common Stock (KRYS) Financials
Key financial figures for Krystal Biotech, Inc. Common Stock (Q1 2026).
- Revenue
- $116M
- Net Income
- $56M
- EPS
- $1.91
- Total Assets
- $1.4B
- Operating Cash Flow
- $80M
Full income statement, balance sheet, and cash flow for Krystal Biotech, Inc. Common Stock on SentiSense.